- {{heading}}
- Ab00256-10.0 Anti-SARS-CoV S glycoprotein [S109]
- SARS Coronavirus
- Human IgG1
- Purified
- In Stock
- Ab00256-23.0 Anti-SARS-CoV S glycoprotein [S109]
- SARS Coronavirus
- Rabbit IgG
- Purified
- In Stock
Recombinant monoclonal antibody to SARS-CoV S glycoprotein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the EBV transformed human B cell clone S109.
Alternative Name(s) of Target: Severe Acute Respiratory Syndrome Coronavirus GP
Immunogen: Made by immortalizing IgG-expressing B cells from recovered SARS patients.
Specificity: SARS-CoV-neutralizing hmAbs, binds to SARS-CoV S glycoprotein, inhibiting the binding of the glycoprotein to human ACE2.
Antibody first published in: Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic Severe Acute Respiratory Syndrome CoronaVirus challenge. JOURNAL OF VIROLOGY, Apr. 2008, p. 3220–3235 PMID:18199635